Published on
August 22, 2024
- 12:15 GMT
FDA Grants Fast Track Designation to Aveta Biomics’ Drug APG-157 for Neoadjuvant Treatment of Head and Neck Cancer
FDA Fast Track Designation of APG-157 Marks Key Step Toward Potential Accelerated Approval in Head & Neck Cancer Treatment BOSTON, MASSACHUSETTS, UNITED STATES, August 22, 2024 /EINPresswire.com/ -- – Aveta Biomics, a pioneering oncology company …
Distribution channels:
Banking, Finance & Investment Industry, Business & Economy
...
